Applied BioCode (Taiwan) Analysis
| 6598 Stock | TWD 24.55 0.20 0.82% |
Applied BioCode holds a debt-to-equity ratio of 0.054. Applied BioCode's financial risk is the risk to Applied BioCode stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Applied BioCode's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Applied BioCode's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Applied Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Applied BioCode's stakeholders.
For many companies, including Applied BioCode, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Applied BioCode, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Applied BioCode's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Applied BioCode's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Applied BioCode is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Applied BioCode to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Applied BioCode is said to be less leveraged. If creditors hold a majority of Applied BioCode's assets, the Company is said to be highly leveraged.
Applied BioCode is overvalued with Real Value of 20.1 and Hype Value of 24.55. The main objective of Applied BioCode stock analysis is to determine its intrinsic value, which is an estimate of what Applied BioCode is worth, separate from its market price. There are two main types of Applied BioCode's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Applied BioCode's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Applied BioCode's stock to identify patterns and trends that may indicate its future price movements.
The Applied BioCode stock is traded in Taiwan on Taiwan Stock Exchange, with the market opening at 09:00:00 and closing at 13:30:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Taiwan. Applied Stock trading window is adjusted to Asia/Shanghai timezone.
Applied |
Applied Stock Analysis Notes
About 43.0% of the company shares are owned by insiders or employees . The book value of Applied BioCode was presently reported as 10.71. The company recorded a loss per share of 2.63. Applied BioCode had not issued any dividends in recent years. Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company was founded in 2016 and is based in Santa Fe Springs, California. APPLIED BIOCODE operates under Medical Devices classification in Taiwan and is traded on Taiwan Stock Exchange. For more info on Applied BioCode please contact the company at 833 246 2633 or go to https://www.apbiocode.com.Applied BioCode Investment Alerts
| Applied BioCode is not yet fully synchronised with the market data | |
| The company reported the revenue of 319.96 M. Net Loss for the year was (165.2 M) with profit before overhead, payroll, taxes, and interest of 189.37 M. | |
| Applied BioCode has accumulated about 819.75 M in cash with (151.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.03. | |
| Roughly 43.0% of the company shares are owned by insiders or employees |
Applied Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.31 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Applied BioCode's market, we take the total number of its shares issued and multiply it by Applied BioCode's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Applied Profitablity
Applied BioCode's profitability indicators refer to fundamental financial ratios that showcase Applied BioCode's ability to generate income relative to its revenue or operating costs. If, let's say, Applied BioCode is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Applied BioCode's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Applied BioCode's profitability requires more research than a typical breakdown of Applied BioCode's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.47) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.47. Applied BioCode Outstanding Bonds
Applied BioCode issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Applied BioCode uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Applied bonds can be classified according to their maturity, which is the date when Applied BioCode has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Applied BioCode Predictive Daily Indicators
Applied BioCode intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Applied BioCode stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Applied BioCode Debt to Cash Allocation
Many companies such as Applied BioCode, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Applied BioCode has accumulated 58.4 M in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Applied BioCode has a current ratio of 13.01, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Applied BioCode until it has trouble settling it off, either with new capital or with free cash flow. So, Applied BioCode's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Applied BioCode sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Applied to invest in growth at high rates of return. When we think about Applied BioCode's use of debt, we should always consider it together with cash and equity.Applied BioCode Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Applied BioCode's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Applied BioCode, which in turn will lower the firm's financial flexibility.Applied BioCode Corporate Bonds Issued
About Applied Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Applied BioCode prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Applied shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Applied BioCode. By using and applying Applied Stock analysis, traders can create a robust methodology for identifying Applied entry and exit points for their positions.
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex testing products for the In-Vitro diagnostics market. The company was founded in 2016 and is based in Santa Fe Springs, California. APPLIED BIOCODE operates under Medical Devices classification in Taiwan and is traded on Taiwan Stock Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Applied BioCode to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Additional Tools for Applied Stock Analysis
When running Applied BioCode's price analysis, check to measure Applied BioCode's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied BioCode is operating at the current time. Most of Applied BioCode's value examination focuses on studying past and present price action to predict the probability of Applied BioCode's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied BioCode's price. Additionally, you may evaluate how the addition of Applied BioCode to your portfolios can decrease your overall portfolio volatility.